Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

SB 526Sesión 2025

Qué cambió entre versiones

16 párrafos cambiaron+251 palabras agregadas−72 eliminadas

El texto resaltado se agregó en la versión más reciente. El texto tachado se eliminó.

SB526 SFAS MartinRules AM #1 3-253-24

LongDellinger 79527965

SenatorThe MartinCommittee on Rules moved to amend the amendmentbill onby pagestriking 1,out section 3,everything after linethe 13,enacting byclause addingand ainserting newin subdivisionlieu (5)thereof tothe read as followsfollowing:

(5) Any prescription dispensed or prescribed pursuant to this article is limited to up to a 30-day supply within a six-month period: Provided, That if more than 10 days is prescribed or dispensed, then the pharmacist shall notify the primary care physician, if identified.

Article 5A. Pharmacist Prescribing authority act.

§30-5A-1. Short title.

This Act shall be known and may be cited as the Pharmacist Prescribing Authority Act.

§30-5A-2. Purpose.

The purpose of this Act is to authorize pharmacists to practice the full extent of their education and training to prescribe low-risk medications to patients.

§30-5A-3. Practice of pharmacy.

The scope of the practice of pharmacy includes all of §30-5-1 et seq. of this code, as well as the prescribing of drugs, drug categories, or devices, excluding controlled substances, that are prescribed in accordance with the product’s federal Food and Drug Administration-approved labeling and that are limited to conditions for which a relevant patient medication history has been taken and:

(1) Do not require a new diagnosis; or

(2) Have a test that is used to guide diagnosis or clinical decision-making that is waived under the federal Clinical Laboratory Improvement Amendments of 1988 that indicates the existence of a condition that is minor and generally self-limiting; or

(3) In the professional judgment of the pharmacist, are patient emergencies.

(4) The pharmacist may, within 72 hours, notify the patient’s primary care physician, if identified, of the test result and any permissible drug, drug categories, or devices that are prescribed.

§30-5A-4. Exemption from review requirements.

Adopted

Rejected

Volver al texto completo